Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
Luckily for you, our job at StockStory is to help you avoid short-term fads by pointing you toward high-quality businesses that can generate sustainable long-term growth. That said, here is one growth stock where the best is yet to come and two whose momentum may slow.
Two Growth Stocks to Sell:
ACV Auctions (ACVA)
One-Year Revenue Growth: +15.9%
Founded in 2014, ACV Auctions (NYSE: ACVA) is an online auction marketplace for car dealers and wholesalers to buy and sell used cars.
Why Are We Hesitant About ACVA?
- High servicing costs result in an inferior gross margin of 27.3% that must be offset through higher volumes
- Highly competitive market means it’s on the never-ending treadmill of sales and marketing spend
ACV Auctions is trading at $5.88 per share, or 10.6x forward EV/EBITDA. Dive into our free research report to see why there are better opportunities than ACVA.
Phibro Animal Health (PAHC)
One-Year Revenue Growth: +26%
With a portfolio of approximately 800 product lines serving farmers and veterinarians in 90 countries, Phibro Animal Health (NASDAQ: PAHC) develops, manufactures, and markets health products for livestock and companion animals, including antibacterials, vaccines, nutritional supplements, and mineral additives.
Why Are We Cautious About PAHC?
- Smaller revenue base of $1.5 billion means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
- Estimated sales growth of 2.2% for the next 12 months implies demand will slow from its two-year trend
- Poor free cash flow margin of 0.8% for the last five years limits its freedom to invest in growth initiatives, execute share buybacks, or pay dividends
Phibro Animal Health’s stock price of $32.36 implies a valuation ratio of 9.9x forward P/E. To fully understand why you should be careful with PAHC, check out our full research report (it’s free).
One Growth Stock to Buy:
StoneX (SNEX)
One-Year Revenue Growth: +23.7%
Originally known as INTL FCStone until its 2020 rebranding, StoneX Group (NASDAQ: SNEX) provides a global financial services network connecting companies, traders, and investors to markets through clearing, execution, and advisory services.
Why Will SNEX Beat the Market?
- Market share has increased this cycle as its 44.3% annual revenue growth over the last two years was exceptional
- Earnings per share grew by 29.6% annually over the last two years, massively outpacing its peers
- Annual tangible book value per share growth of 16.9% over the past five years was outstanding, reflecting strong capital accumulation this cycle
At $114.28 per share, StoneX trades at 3x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
